MASH / MASLD

Definition

Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — the 2023 consensus renamings of NASH and NAFLD. Characterized by hepatic fat accumulation plus inflammation (MASH) or without (MASLD), driven by insulin resistance + obesity. SYNERGY-NASH (Loomba 2024 NEJM, tirzepatide) and ESSENCE (semaglutide phase 3) showed substantial fibrosis improvement, positioning GLP-1s as the first systemic therapies for MASH outside the FXR agonist resmetirom.

Tirzepatide trial reading list (incl. SYNERGY-NASH) →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Mechanism

• GLP-1 receptor
• GIP receptor
• Dual agonist
• Gastric emptying
• Food noise
• Triple agonist
• Amylin
• GLP-1 tachyphylaxis
• Non-peptide GLP-1 agonist
• A1C (glycated hemoglobin)

Looking for more depth?

• Tirzepatide trial reading list (incl. SYNERGY-NASH)
• Browse the full GLP-1 glossary (61 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers